Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBITDA Margin (2020 - 2025)

Xeris Biopharma Holdings' EBITDA Margin history spans 6 years, with the latest figure at 12.91% for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 2144.0% year-over-year to 12.91%, compared with a TTM value of 0.19% through Dec 2025, up 2719.0%, and an annual FY2025 reading of 0.19%, up 2719.0% over the prior year.
  • EBITDA Margin for Q4 2025 was 12.91% at Xeris Biopharma Holdings, up from 0.83% in the prior quarter.
  • The five-year high for EBITDA Margin was 12.91% in Q4 2025, with the low at 309.06% in Q2 2021.
  • Average EBITDA Margin over 5 years is 82.65%, with a median of 42.85% recorded in 2022.
  • Year-over-year, EBITDA Margin plummeted -6386bps in 2021 and then soared 20564bps in 2022.
  • Tracing XERS's EBITDA Margin over 5 years: stood at 237.04% in 2021, then skyrocketed by 84bps to 38.97% in 2022, then grew by 23bps to 30.11% in 2023, then skyrocketed by 72bps to 8.52% in 2024, then surged by 252bps to 12.91% in 2025.
  • Per Business Quant, the three most recent readings for XERS's EBITDA Margin are 12.91% (Q4 2025), 0.83% (Q3 2025), and 2.69% (Q2 2025).